Ensysce reports FY2023 net loss of $10.6M; cash $1.1M; FDA Breakthrough for PF614-MPAR

Ensysce Biosciences, Inc.

Net loss Q4 2023 $3.5M vs $5.5M; full year $10.6M vs $25.1M (prior year).
Cash $1.1M at Dec 31, 2023; raised $6.8M from warrant exercises in Jan & Feb 2024.
R&D expenses fell to $2.2M (Q4) and $7.6M (FY) from $6.4M and $19.8M.
FDA granted Breakthrough Therapy designation for PF614-MPAR in January 2024.
Phase 3 enrollment for PF614 expected H2 2024 after positive End-of-Phase 2 meeting.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Ensysce Biosciences, Inc. reported financial results for the fourth quarter and full year of 2023.

Period: the fourth quarter and full year of 2023
Result: reported results

Exact text from the filing

On March 15, 2024, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Ensysce Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-010014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.